Format

Send to

Choose Destination
Mol Ther. 2019 Jan 2;27(1):118-129. doi: 10.1016/j.ymthe.2018.11.003. Epub 2018 Nov 13.

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.

Author information

1
Adverum Biotechnologies, Menlo Park, CA, USA.
2
Stanford University, Palo Alto, CA, USA.
3
RxGen Inc., New Haven, CT, USA.
4
Weill Cornell Medical College, New York, NY, USA.
5
Adverum Biotechnologies, Menlo Park, CA, USA. Electronic address: mehdi@adverum.com.

Abstract

Inhibition of vascular endothelial growth factor, a key contributor to the choroidal neovascularization associated with wet age-related macular degeneration, is the mode of action of several approved therapies, including aflibercept, which requires frequent intravitreal injections to provide clinical benefit. Lack of compliance with the dosing schedule may result in recurrence of active wet macular degeneration, leading to irreversible vision impairment. Gene therapy providing sustained anti-vascular endothelial growth factor levels in the retina following a single injection could drastically reduce the treatment burden and improve visual outcomes. ADVM-022, an adeno-associated virus vector encoding aflibercept, is optimized for intravitreal delivery and strong protein expression. Here, we report the long-term expression and efficacy of ADVM-022-derived aflibercept in a laser-induced choroidal neovascularization model in non-human primates. Intravitreal administration of ADVM-022 was well tolerated and resulted in sustained aflibercept levels. In addition, ADVM-022 administration 13 months before lasering prevented the occurrence of clinically relevant choroidal neovascularization lesions, similar to animals that received a bolus of intravitreal aflibercept (standard of care) at the time of lesioning. These results demonstrate that a single intravitreal administration of ADVM-022 may provide a safe and effective long-term treatment option for wet macular degeneration and may ultimately improve patients' visual outcomes.

KEYWORDS:

AAV; age-related macular degeneration; gene therapy

PMID:
30528929
PMCID:
PMC6319194
DOI:
10.1016/j.ymthe.2018.11.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center